Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03881774
Recruitment Status : Recruiting
First Posted : March 19, 2019
Last Update Posted : March 21, 2019
Sponsor:
Collaborator:
Henan Hualong Biotechnology Company
Information provided by (Responsible Party):
Henan Cancer Hospital

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : January 31, 2021
Estimated Study Completion Date : January 31, 2022